Scancell Holdings PLC - Oxford, England-based immunotherapies for treatment of cancer and infectious disease - Says the first subject has been dosed in its Covidity clinical trial being conducted at the University of Cape Town Lung Institute in South Africa. Says the objectives of phase one of the trial are to assess the safety and immunogenicity of two vaccine candidates, SCOV1 and SCOV2, which target the original and variant SAR-CoV-2 viruses, respectively, in healthy pre-vaccinated subjects. The study will also determine the immunological responses induced by the vaccines administered by two alternative injection routes using two PharmaJet needle-free delivery systems, it adds.
Chief Executive Officer Lindy Durrant says: "We are delighted that we have been able to start this trial so quickly following regulatory approval in South Africa. The Scancell team and collaborators have worked diligently since the start of the pandemic to design, characterise, manufacture and deliver this second generation Covid-19 vaccine and we look forward to evaluating its clinical potential with our colleagues in South Africa."
Current stock price: 22.60 pence
Year-to-date change: up 61%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)